将加巴喷丁作为滥用药物进行监管：肯塔基州社区药剂师的调查研究。
Regulating gabapentin as a drug of abuse: A survey study of Kentucky community pharmacists.
出版信息
J Am Pharm Assoc (2003). 2019 May-Jun;59(3):379-382. doi: 10.1016/j.japh.2018.12.018. Epub 2019 Feb 18.
OBJECTIVES
As the number of gabapentin prescriptions has increased, so have reports of its misuse and diversion. This trend has led some states to closer monitoring of gabapentin dispensing through prescription drug monitoring programs (PDMPs). The objective of this study was to collect and analyze Kentucky community pharmacists' perceptions of gabapentin misuse and diversion, and their support or opposition to regulatory efforts to reclassify the drug as a controlled substance (CS).
METHODS
Responses were collected using an online survey sent by e-mail to all pharmacists practicing in Kentucky in August 2016. The survey collected basic demographic characteristics and pharmacists' experience with gabapentin dispensing. Descriptive statistics were calculated using question response frequencies. Pearson's chi-squared statistics were calculated to examine the distribution of support for gabapentin as a CS in Kentucky across each of the categories of the individual variables. Logistic regression was used to estimate the effects of pharmacist demographic characteristics and experiences with gabapentin on their support of gabapentin reclassification as a CS.
RESULTS
One thousand seven hundred sixty-nine surveys were collected (response rate = 34.2%). Responding community pharmacists (n = 1084) believe that the abuse and diversion of gabapentin are a problem in their communities, with 9 in 10 (89.6%) indicating that they agree or strongly agree. More than three-fourths (87.5%) indicated support for reclassifying gabapentin as a CS. Common reasons for opposition to gabapentin regulatory changes were that they would not reduce or eliminate abuse (45.8%) and that they would be an inconvenience to patients (17.0%). Pharmacists practicing in independent pharmacies and pharmacists in practice greater than 20 years were less likely to indicate support for gabapentin reclassification.
CONCLUSION
Kentucky community pharmacists express considerable concern over the possible misuse and diversion of gabapentin and widely support regulatory changes reclassifying gabapentin as a CS.
目的
随着加巴喷丁处方数量的增加，其滥用和转移的报告也越来越多。这一趋势导致一些州通过处方药物监测计划（PDMP）对加巴喷丁的配药进行更密切的监测。本研究的目的是收集和分析肯塔基州社区药剂师对加巴喷丁滥用和转移的看法，以及他们对将该药物重新归类为受控物质（CS）的监管努力的支持或反对。
方法
2016 年 8 月，通过电子邮件向肯塔基州所有执业药剂师发送在线调查，收集回复。该调查收集了基本人口统计学特征和药剂师配药加巴喷丁的经验。使用问题回复频率计算描述性统计数据。使用 Pearson 卡方检验计算支持肯塔基州将加巴喷丁作为 CS 的分布情况，以检查每个个体变量类别。使用逻辑回归估计药剂师人口统计学特征和加巴喷丁经验对他们支持将加巴喷丁重新归类为 CS 的影响。
结果
共收集了 1769 份调查（回复率为 34.2%）。回应的社区药剂师（n=1084）认为加巴喷丁的滥用和转移是他们社区的一个问题，其中 90%（89.6%）表示同意或强烈同意。超过四分之三（87.5%）表示支持将加巴喷丁重新归类为 CS。反对加巴喷丁监管变化的常见原因是，它们不会减少或消除滥用（45.8%），并且对患者不方便（17.0%）。在独立药房执业的药剂师和执业超过 20 年的药剂师不太可能表示支持加巴喷丁重新分类。
结论
肯塔基州社区药剂师对加巴喷丁可能的滥用和转移表示极大关注，并广泛支持将加巴喷丁重新归类为 CS 的监管变化。
Zotero 插件